The first national Beijing original research new drug obtains the "going global" price certification.

The Chinese Drug Price Registration System issued the first overseas price certificate in the country, with a Beijing original research pharmaceutical company taking the lead. In other words, this original research drug has obtained authoritative pricing basis in the international market, and the speed of entering the international market is expected to accelerate. The "winner" of the first price certificate is the world's first original new drug for the topical treatment of infant hemangioma, filling a clinical treatment gap in this area of disease. This is one of the more common benign tumors in infants and young children, with a global incidence of about 5% to 12%, and there is a considerable demand for the drug in the overseas market. The pharmaceutical company that received the price certificate this time is a small and medium-sized enterprise. The drug was approved for marketing by the National Medical Products Administration on September 30, 2025, and had not been priced overseas prior to that.